BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

LifeScience Antibody Drug Conjugates

Innovent Secures Second NMPA Breakthrough Therapy Designation for IBI363 in Advanced Lung Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality m...

June 05, 2025 | News

China Approves First Homegrown ADC, Trastuzumab Rezetecan, for HER2-Mutant Lung Cancer

The National Medical Products Administration has recently granted approval for Trastuzumab rezetecan, China's first domestically develo...

May 30, 2025 | News

RemeGen’s Telitacicept Approved in China as First Dual-Target Biologic for Generalized Myasthenia Gravis

RemeGen Co., Ltd.(688331.SH / 09995.HK) announced that Telitacicept has officially been approved for marketing in China by the National Medical Produc...

May 28, 2025 | News

Avenzo Therapeutics and Duality Biotherapeutics Gain FDA Clearance for EGFR/HER3 Bispecific ADC AVZO-1418/DB-1418

Duality Biotherapeutics ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-gen...

May 26, 2025 | News

DualityBio and Avenzo Receive FDA IND Clearance for Novel EGFR/HER3 Bispecific ADC

Duality Biotherapeutics partner Avenzo Therapeutics, Inc. a clinical-stage biotechnology company developing next-generation oncology therapies, announced c...

May 23, 2025 | News

Kelun-Biotech's Fourth Indication for ADC sac-TMT Accepted for Priority Review in China

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that a new indication application (the "Application") for the Company's trophob...

May 22, 2025 | News

Antengene and MSD Enter Global Clinical Collaboration to Evaluate ATG-022 and KEYTRUDA® Combo in Solid Tumors

Antengene Corporation Limited , a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercial...

May 21, 2025 | News

Fujifilm Validates Cancer-Targeting Potential of Peptide-Oligonucleotide Conjugates Using Proprietary Cyclic Peptide Library

FUJIFILM Corporation announces the successful validation of the cancer cell-targeting potential of its peptide-oligonucleotide conjugates. This validation ...

May 21, 2025 | News

Minghui Pharma Licenses B7-H3 ADC MHB088C to Qilu for Greater China in RMB 1.345 Billion Deal

Minghui Pharmaceutical , a late-stage clinical biopharmaceutical company, announced an exclusive licensing and collaboration agreement with Qilu Phar...

May 12, 2025 | News

BioDlink Supports Junshi Biosciences in Achieving IND Approval for JS212, Its First Bispecific ADC

BioDlink congratulates Junshi Biosciences on receiving IND approval from China's NMPA for JS212, the company...

May 09, 2025 | News

Ajinomoto and RIBOMIC Advance Next-Gen Aptamer Therapeutics with Extended Half-Life Using AJICAP® Technology

Ajinomoto Co., Inc. has been conducting joint research* with RIBOMIC Inc. (President: Yoshikazu Nakamura, Headquarters: Minato-ku, Tokyo, hereinafter refer...

May 07, 2025 | News

PCI Pharma Services Acquires Ajinomoto Althea’s Altair to Build Global Powerhouse in Aseptic Filling and Advanced Drug Delivery

PCI Pharma Services ("PCI") is pleased to announce the launch of Ajinomoto Althea, the world's leading contract research and manufacturing organi...

May 05, 2025 | News

Innovent Biologics Doses First Patient in Global Phase 1 Trial of IBI3020, a First-in-Class Dual-Payload CEACAM5 ADC

Innovent Biologics, a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment ...

April 30, 2025 | News

Keymed Biosciences Advances CDH17-Targeted ADC CM518D1 Into Phase I/II Trials for Solid Tumors in China

Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced CM518D1, a CDH17-targeted antibody-drug conjugate (ADC) develop...

April 28, 2025 | News

Stay Connected